Particle.news
Download on the App Store

Breakthrough T1D Backs CAR-Treg Beta-Cell Therapy as UChicago Reports PD‑L1 mRNA Results

Both efforts remain preclinical as teams focus on durability, delivery, dosing, safety, then translation to human testing.

Overview

  • Medical University of South Carolina researchers led by Leonardo Ferreira received $1 million from Breakthrough T1D to pair stem cell–derived beta cells with CAR-engineered regulatory T cells designed to protect the graft.
  • Humanized-mouse studies of the MUSC approach showed protection lasting up to one month, prompting expanded work to extend benefit and refine dosing and delivery.
  • University of Chicago scientists reported a nanoparticle system that delivers PD-L1 mRNA to beta cells, delaying disease in mice and showing activity in models using human beta-cell transplants.
  • The UChicago findings were published in Cell Reports Medicine and the study was funded by Breakthrough T1D and the National Institutes of Health.
  • Researchers emphasize potential to avoid systemic immunosuppression and to scale lab-grown cell supplies, though both strategies require further safety and translational studies before any human trials.